(Q39026766)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

review article

1 reference

title

Endometrial Carcinoma: Specific Targeted Pathways (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

main subject

endometrial carcinoma

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Xavier Matias-Guiu Guia

10

object named as

Xavier Matias-Guiu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

author name string

Nuria Eritja

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Andree Yeramian

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Bo-Juen Chen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Eugenia Ortega

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Eva Colas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Miguel Abal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Xavier Dolcet

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Jaume Reventos

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

language of work or name

English

0 references

publication date

1 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

Advances in Experimental Medicine and Biology

28 March 2020

number of pages

59

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

volume

943

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

page(s)

149-207

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

Pten is essential for embryonic development and tumour suppression

28 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Long-term estradiol exposure is a direct mitogen for insulin/EGF-primed endometrial cells and drives PTEN loss-induced hyperplasic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Systematic identification of genomic markers of drug sensitivity in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Regulation of protein kinase cascades by protein phosphatase 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Integrated genomic characterization of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Mutations of the human PTEN gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Endometrial carcinoma: pathology and genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

DNA mismatch repair deficiency in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

PI3K/Akt and ERK1/2 signalling pathways are involved in endometrial cell migration induced by 17beta-estradiol and growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

PI3K pathway dependencies in endometrioid endometrial cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Unraveling the microenvironmental influences on the normal mammary gland and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

RAD001 (Everolimus) Can prevent tamoxifen-related endometrial and stromal hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Chemically targeting the PI3K family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Ras oncogenes: split personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

GEFs and GAPs: critical elements in the control of small G proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Regulation of small GTPases by GEFs, GAPs, and GDIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Raf-interactome in tuning the complexity and diversity of Raf function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

"RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

MEK1/2 dual-specificity protein kinases: structure and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

ERK1/2 MAP kinases: structure, function, and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

RAS oncogenes: weaving a tumorigenic web

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A comprehensive survey of Ras mutations in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Isoform-specific ras functions in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Hyperactive Ras in developmental disorders and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Dragging ras back in the ring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Mutations of the Ki-ras oncogene in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Mutational analysis of the BRAF gene in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Rapid induction of uterine endometrial proliferative lesions in transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) given a single intraperitoneal injection of N-ethyl-N-nitrosourea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Targeting RAS-ERK signalling in cancer: promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

MEK1/2 inhibitors in the treatment of gynecologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A point mutation in the neu oncogene mimics ligand induction of receptor aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Oncogene alterations in endometrial carcinosarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Gene expression profiling and cancer-related pathways in type I endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Roles of PDGF in animal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Regulation of proliferation, motility, and contractility of human endometrial stromal cells by platelet-derived growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Platelet-derived growth factor promotes endometrial epithelial cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Over-expression of platelet-derived growth factor-D promotes tumor growth and invasion in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of imatinib mesylate-targeted kinases in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

PDGFR-alpha as a potential therapeutic target in uterine sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Identification of a ligand for the c-kit proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Temporal expression and location of colony-stimulating factor 1 (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Regulation of colony-stimulating factor 1 during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Colony-Stimulating Factor-1 and c-fmsExpression in Human Endometrial Tissues and Placenta during the Menstrual Cycle and Early Pregnancy*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Apparent role of the macrophage growth factor, CSF-1, in placental development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Insulin-like growth factors in endometrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Pathobiology of ALK+ anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The Met tyrosine kinase receptor in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Effects of hepatocyte growth factor on the expression of matrix metalloproteinases and their tissue inhibitors during the endometrial cancer invasion in a three-dimensional coculture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The role of fibroblast growth factors in tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Receptor specificity of the fibroblast growth factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Mechanisms of FGFR-mediated carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Fibroblast growth factor-9 is an endometrial stromal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Regulation of endometrial fibroblast growth factor 7 (FGF-7) and its receptor FGFR2IIIb in gilts after sex steroid replacements, and during the estrous cycle and early gestation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of epidermal growth factor receptor (EGF-R), vascular endothelial growth factor receptor (VEGF-R) and fibroblast growth factor receptor (FGF-R) systems in porcine oviduct and endometrium during the time of implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of Eph receptor tyrosine kinases and their ligands in chick embryonic motor neurons and hindlimb muscles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of the Tyro4/Mek4/Cek4 gene specifically marks a subset of embryonic motor neurons and their muscle targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The history and future of targeting cyclin-dependent kinases in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Smads as transcriptional co-modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Structural insights into anaphase-promoting complex function and mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

DNA replication in eukaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Inhibitory effect of 2-(piperidinoethoxyphenyl)-3-(4-hydroxyphenyl)-2H-benzo(b)pyran (K-1) on human primary endometrial hyperplasial cells mediated via combined suppression of Wnt/β-catenin signaling and PI3K/Akt survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression and clinical significance of FAK and Src proteins in human endometrial adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Highlights of the Latest Advances in Research on CDK Inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Wnt/β-catenin signaling and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Pocket proteins and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Growth factors from murine sarcoma virus-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Role of canonical Wnt signaling in endometrial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

SRC kinase and mitogen-activated protein kinases in the progression from normal to malignant endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Defining the role of Wnt/beta-catenin signaling in the survival, proliferation, and self-renewal of human embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Cyclin D1 localizes in the cytoplasm of keratinocytes during skin differentiation and regulates cell-matrix adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Targeting Src in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Uterine epithelial cell proliferation and endometrial hyperplasia: evidence from a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

RNF43 is frequently mutated in colorectal and endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Signal transduction of beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Identification of c-MYC as a target of the APC pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Entry into mitosis: a solution to the decades-long enigma of MPF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Mutations of the beta-catenin gene in endometrial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Wnt and calcium signaling: beta-catenin-independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Safely targeting cancer stem cells via selective catenin coactivator antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Focal adhesion kinase overexpression in endometrial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

21 January 2018

Cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

21 January 2018

The hunting of the Src

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

TGF-β signaling in development and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Molecular pathology of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

In vitro effects of a small-molecule antagonist of the Tcf/ß-catenin complex on endometrial and endometriotic cells of patients with endometriosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Latent transforming growth factor-beta: structural features and mechanisms of activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Putative tyrosine kinases expressed in K-562 human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Phosphorylation of the Drosophila adherens junction protein Armadillo: roles for wingless signal and zeste-white 3 kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Down-regulated expression of transforming growth factor beta 1 mRNA in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Wnt signalling in stem cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Type beta transforming growth factor: a bifunctional regulator of cellular growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Signaling through focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A critical role for the EphA3 receptor tyrosine kinase in heart development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Pressure activates colon cancer cell adhesion by inside-out focal adhesion complex and actin cytoskeletal signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Cellular functions regulated by Src family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Analysis of microsatellite instability and loss of heterozygosity in uterine endometrial adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metallopro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Wnt signaling in osteoblasts and bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Mechanism of activation of the TGF-beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Targeting Src family kinases in anti-cancer therapies: turning promise into triumph

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Non-Smad pathways in TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A novel wnt regulatory axis in endometrioid endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Low frequency ofBRAFandCDKN2Amutations in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Tyrosine Kinase Receptor Status in Endometrial Stromal Sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Low Frequency of BRAF Mutations in Endometrial and in Cervical Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

FGFR2 alterations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Point mutations at codon 12 of C-K-ras in human endometrial carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

K-ras mutations in endometrial carcinomas with microsatellite instability

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Tyrosine kinases as targets for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

RTK mutations and human syndromes: when good receptors turn bad

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of the epidermal growth factor system in endometrioid endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Current status of molecular-targeted drugs for endometrial cancer (Review).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of colony-stimulating factor-1 in the human uterus and placenta

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of the colony-stimulating factor-1 receptor (c-fms proto-oncogene product) in the human uterus and placenta

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The cytokine CSF-1 (M-CSF) expressed by endometrial carcinomas in vivo and in vitro, may also be a circulating tumor marker of neoplastic disease activity in endometrial carcinoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The proto-oncogene c-fms is overexpressed in endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Insulin-like growth factor I receptor signaling--overlapping or redundant pathways?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Insulin-like growth factor I (IGF-I), IGF-I receptors, and IGF binding proteins 1-4 in human uterine tissue: tissue localization and IGF-I action in endometrial stromal and myometrial smooth muscle cells in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The insulin and insulin-like growth factor receptor family in neoplasia: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Loss of IGF-II imprinting in endometrial tumors: overexpression in carcinosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Hepatocyte growth factor (HGF) stimulates tumour invasiveness in papillary carcinoma of the thyroid

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Transforming growth factor-beta 1 mediates communication between human endometrial carcinoma cells and stromal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Integrins and signal transduction pathways: the road taken

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

[The serine/threonine kinases that control cell cycle progression as therapeutic targets].

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Loss of Smad4 protein expression occurs infrequently in endometrial carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

The association between p53 expression, stage and histological features in endometrial cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Endoglin (CD105) expression in endometrial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-43139-0_6

Retracted: Overexpression of the Insulin Receptor Isoform A Promotes Endometrial Carcinoma Cell Growth

31 March 2020

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1371/JOURNAL.PONE.0069001

Identifiers

DOI

10.1007/978-3-319-43139-0_6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27910068%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference